Literature DB >> 15727574

Epidemiology of life-threatening and lethal anaphylaxis: a review.

D A Moneret-Vautrin1, M Morisset, J Flabbee, E Beaudouin, G Kanny.   

Abstract

Severe anaphylaxis is a systemic reaction affecting two or more organs or systems and is due to the release of active mediators from mast cells and basophils. A four-grade classification routinely places 'severe' anaphylaxis in grades 3 and 4 (death could be graded as grade 5). Studies are underway to determine the prevalence of severe and lethal anaphylaxis in different populations and the relative frequencies of food, drug, latex and Hymenoptera anaphylaxis. These studies will also analyse the risk arising from the lack of preventive measures applied in schools (personalized management protocols) and from the insufficient use of self-injected adrenalin. Allergy-related conditions may account for 0.2-1% of emergency consultations. Severe anaphylaxis affects 1-3 per 10 000 people, but for the United States and Australia figures are even higher. It is estimated to cause death in 0.65-2% of patients, i.e. 1-3 per million people. An increased prevalence has been revealed by monitoring hospitalized populations by reference to the international classification of disease (ICD) codes. The relative frequency of aetiological factors of allergy (food, drugs, insects and latex) varies in different studies. Food, drug and Hymenoptera allergies are potentially lethal. The risk of food-mediated anaphylaxis can be assessed from the number of personalized management protocols in French schools: 0.065%. Another means of assessment may be the rate of adrenalin prescriptions. However, an overestimation of the anaphylaxis risk may result from this method (0.95% of Canadian children). Data from the literature leads to several possibilities. First, a definition of severe anaphylaxis should be agreed. Secondly, prospective, multicentre enquiries, using ICD codes, should be implemented. Moreover, the high number of anaphylaxis cases for which the aetiology is not identified, and the variation in aetiology in the published series, indicate that a closer cooperation between emergency specialists and allergists is essential.

Entities:  

Mesh:

Year:  2005        PMID: 15727574     DOI: 10.1111/j.1398-9995.2005.00785.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  46 in total

1.  Teicoplanin anaphylaxis associated with surgical prophylaxis.

Authors:  Tariq Azamgarhi; Ashik Shah; Simon Warren
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

2.  IgE-mediated anaphylactic reactions to neuromuscular blocking agents: can they be prevented?

Authors:  E Florvaag; S G O Johansson
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

3.  Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Authors:  Ulrike Baranyi; Birgit Linhart; Nina Pilat; Martina Gattringer; Jessamyn Bagley; Ferdinand Muehlbacher; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

4.  Case fatality and population mortality associated with anaphylaxis in the United States.

Authors:  Larry Ma; Theodore M Danoff; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-12-14       Impact factor: 10.793

5.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

Review 6.  [Management of anaphylaxis. Part 1: Causes and pathophysiology].

Authors:  A Glowania; U Goebel; L Klimek
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

Review 7.  NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population.

Authors:  A Wesley Burks; Stacie M Jones; Joshua A Boyce; Scott H Sicherer; Robert A Wood; Amal Assa'ad; Hugh A Sampson
Journal:  Pediatrics       Date:  2011-10-10       Impact factor: 7.124

8.  [Food-associated anaphylaxis. Data from the anaphylaxis registry].

Authors:  S Dölle; S Hompes; J Grünhagen; M Worm
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

Review 9.  [Anaphylaxis. Clinical manifestations and diagnosis].

Authors:  B Przybilla; J Ring; F Ruëff
Journal:  Hautarzt       Date:  2007-12       Impact factor: 0.751

10.  Adrenaline in the Acute Treatment of Anaphylaxis.

Authors:  Johannes Ring; Ludger Klimek; Margitta Worm
Journal:  Dtsch Arztebl Int       Date:  2018-08-06       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.